Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New ...
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
Barchart on MSN2d
Gilead Sciences - Leader in HIV Medicines
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Nasdaq3d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Biktarvy Demonstrates High Rates of Viral Suppression in People with HIV/HBV Coinfection ALLIANCE (NCT03547908) is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG ...
GlobalData on MSN3d
MSD to push for approval of HIV combo after Phase III success
MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.
Nasdaq4d
Gilead Presents Encouraging Long-term Data For Biktarvy In People With HIV And HBV Coinfection
(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it presented encouraging long-term data from ALLIANCE study. ALLIANCE is an ongoing Phase 3 study to evaluate Biktarvy versus dolutegravir ...
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The Financial Express2d
Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.
Morningstar4d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
“Gilead is fueling the next wave of innovation ... vital importance of catalyzing research reaching towards a cure.” Biktarvy Demonstrates High Rates of Viral Suppression in People with ...